SEKAL provides surgical and therapeutic solutions for various eye conditions, including refractive surgery and cataract treatments.

SEKAL

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

Archer-Daniels-Midland Company procures, transports, stores, processes, and merchandises agricultural commodities, products, and ingredients in the United States, Switzerland, Cayman Islands, Brazil, Mexico, the United Kingdom, and internationally. The company operates through three segments: Ag Services and Oilseeds, Carbohydrate Solutions, and Nutrition. It procures, stores, cleans, and transports agricultural raw materials, such as oilseeds, corn, wheat, milo, oats, and barley. The company also engages in the agricultural commodity and feed product import, export, and distribution; and structured trade finance activities. In addition, it offers vegetable oils and protein meals; ingredients for the food, feed, energy, and industrial customers; crude vegetable oils, salad oils, margarine, shortening, and other food products; and partially refined oils to produce biodiesel and glycols for use in chemicals, paints, and other industrial products. Further, the company provides peanuts, peanut-derived ingredients, and cotton cellulose pulp; sweeteners, corn and wheat starches, syrup, glucose, wheat flour, and dextrose; alcohol and other food and animal feed ingredients; ethyl alcohol and ethanol; corn gluten feed and meal; distillers' grains; and citric acids. Additionally, the company provides natural flavors, flavor systems, natural colors, proteins, emulsifiers, soluble fiber, polyols, hydrocolloids, and natural health and nutrition products, including probiotics, prebiotics, enzymes, and botanical extracts; and other specialty food and feed ingredients; edible beans; formula feeds, and animal health and nutrition products; and contract and private label pet treats and foods. It also offers futures commission merchant; commodity brokerage services; cash margins and securities pledged to commodity exchange clearinghouses; and cash pledged as security under certain insurance arrangements. The company was founded in 1902 and is headquartered in Chicago, Illinois.

Archer-Daniels-Midland Company

CooperVision is a company that manufactures and sells contact lenses and related products.

Metric
Company Name	SEKAL	AbbVie Inc.	Archer-Daniels-Midland Company	CooperVision
Symbol		ABBV	ADM
MSH ID	IT:LASEK	COM:ABBVIE	COM:ADM	COM:COOPERVISION
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Consumer Defensive	Healthcare & Health Services
Industry	Medical Services	Drug Manufacturers - General	Agricultural Farm Products	Medical Devices and Supplies
Country	IT	US	US	US
Stage
Employee Count		50K	40.21K	10.00K
Website	lasek.it	abbvie.com	adm.com	coopervision.com
LinkedIn			adm
Founders

Metric
Market Cap		296.91B	31.76B
Enterprise Value
Monthly Web Traffic	292	1.18M	229.04K	402.65K
Web Traffic Growth	0.54	0.51	-0.22	0.33
Valuation
Raised Capital		15B

Metric
Revenue	54.32B	93.97B
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.54B	6.28B
EBITDA	18.10B	3.94B
Operating Income	17.43B	2.88B
Net Income	4.86B	3.48B
EPS	2.75	6.44
Diluted EPS	2.74	6.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72	0.07
Operating Profit Margin	0.27	0.04
EBITDA Margin	0.33	0.04
Net Profit Margin	0.11	0.04
Return on Equity	0.57	0.14
Return on Assets	0.04	0.06
Return on Capital Employed	0.15	0.11

IT:LASEK

SEKAL

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	46.58	7.26
P/B Ratio	25.09	1.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36	0.35
EV Multiple	17.44	5.47

Metric
Days Sales Outstanding	75.54	25.00
Days Payables Outstanding		21.38
Days Inventory Outstanding	102.41	50.10
Operating Cycle	181.71	75.60
Cash Conversion Cycle	179.57	64.11
Asset Turnover	0.40	1.72

Metric
Operating Cash Flow	22.84B	4.46B
Free Cash Flow	22.06B	2.97B
Cash Flow to Debt	0.38	0.66
Operating Cash Flow/Sales	0.42	0.07
Free Cash Flow Yield	0.08	0.02

Metric
Cash & Equivalents	12.81B	5.39B
Accounts Receivable	66M	737M
Inventory	4.10B	11.96B
Goodwill	32.29B	4.10B
Debt to Capitalization	0.91	0.35
Debt to Assets	0.45	0.17
Current Ratio	0.96	1.69
Quick Ratio	0.83	0.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.00
R&D to Revenue	0.14
SG&A to Revenue